Two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), received Emergency Use Authorization from the US Food and Drug Administration. Despite high efficacy and few adverse
No takes yet. Share an insight, caveat, or question.
González et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: